Literature DB >> 15128884

Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients.

Kosaku Nitta1, Takashi Akiba, Keiko Uchida, Shigeru Otsubo, Takashi Takei, Wako Yumura, Takashi Kabaya, Hiroshi Nihei.   

Abstract

BACKGROUND: Osteoprotegerin (OPG) is a glycoprotein that inhibits osteoclast differentiation and activity. OPG-deficient mice develop severe osteoporosis and medial arterial calcification. The expression of OPG is detected in early atherosclerotic lesions in non-uraemic patients. We examined whether serum OPG is associated with aortic calcification in haemodialysis patients.
METHODS: Serum OPG was measured in 102 patients who were undergoing haemodialysis. The aortic calcification index (ACI) was assessed by computed tomography scans.
RESULTS: Serum OPG level, measured by enzyme-linked immunosorbent assay, was significantly greater in patients with higher ACI than in those with lower ACI. There was a direct relationship between ACI and serum OPG levels and a positive association between OPG and ACI (r = 0.483, P<0.0001). Multiple regression analyses indicated that serum OPG levels were independently associated with the severity of aortic calcification (P<0.0001).
CONCLUSIONS: These findings show that serum OPG levels are associated with the extent of vascular calcification, suggesting that OPG may be involved in the development of vascular calcification in haemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15128884     DOI: 10.1093/ndt/gfh263

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  26 in total

Review 1.  Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication.

Authors:  Sinee Disthabanchong
Journal:  World J Nephrol       Date:  2012-04-06

2.  Denosumab in postmenopausal osteoporosis: what the clinician needs to know.

Authors:  E Michael Lewiecki
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-02       Impact factor: 5.346

3.  Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality.

Authors:  Wolfgang Lieb; Philimon Gona; Martin G Larson; Joseph M Massaro; Izabella Lipinska; John F Keaney; Jian Rong; Diane Corey; Udo Hoffmann; Caroline S Fox; Ramachandran S Vasan; Emelia J Benjamin; Christopher J O'Donnell; Sekar Kathiresan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-06       Impact factor: 8.311

4.  Receptor activator of nuclear factor κB ligand/osteoprotegerin axis and vascular calcifications in patients with chronic kidney disease.

Authors:  Michalis Spartalis; Aikaterini Papagianni
Journal:  World J Nephrol       Date:  2016-01-06

5.  PKA-induced receptor activator of NF-kappaB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification.

Authors:  Wendy Tseng; Lucia S Graham; Yifan Geng; Aneela Reddy; Jinxiu Lu; Rita B Effros; Linda Demer; Yin Tintut
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

6.  Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease.

Authors:  Pinar Demir; Fusun Erdenen; Hale Aral; Turker Emre; Sennur Kose; Esma Altunoglu; Anil Dolgun; Berrin Bercik Inal; Aydin Turkmen
Journal:  J Clin Lab Anal       Date:  2016-03-17       Impact factor: 2.352

7.  Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.

Authors:  Sean Morony; Yin Tintut; Zina Zhang; Russell C Cattley; Gwyneth Van; Denise Dwyer; Marina Stolina; Paul J Kostenuik; Linda L Demer
Journal:  Circulation       Date:  2008-01-02       Impact factor: 29.690

8.  Determinants of the intima-media thickness in children and adolescents with chronic kidney disease.

Authors:  Helena Ziolkowska; Michal Brzewski; Maria Roszkowska-Blaim
Journal:  Pediatr Nephrol       Date:  2008-01-29       Impact factor: 3.714

Review 9.  Regulatory circuits controlling vascular cell calcification.

Authors:  Tamer Sallam; Henry Cheng; Linda L Demer; Yin Tintut
Journal:  Cell Mol Life Sci       Date:  2012-12-27       Impact factor: 9.261

Review 10.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

Authors:  Ann E Kearns; Sundeep Khosla; Paul J Kostenuik
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.